ATRA · Atara Biotherapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $516.0K | - | $3.45M | $17.57M | $27.36M | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $164.0K | - | $2.92M | $7.31M | $27.43M | - | $43.92M | $33.33M | $45.51M | - |
| SG&A | $3.60M | - | $3.99M | $6.51M | $11.47M | - | $10.42M | $8.91M | $11.11M | - |
| Total Operating Expenses | $3.88M | - | $7.03M | $14.38M | $59.35M | - | $61.95M | $72.37M | $58.60M | - |
| D&A | $29.0K | - | - | - | $1.79M | - | $600.0K | $700.0K | $1.39M | - |
| Operating Income | ($3.37M) | - | ($3.57M) | $3.20M | $38.80M | - | ($21.76M) | ($18.23M) | ($31.25M) | - |
| Interest Expense | $830.0K | - | $909.0K | $972.0K | $1.02M | - | $1.18M | $1.26M | $1.15M | - |
| Income Tax | $0 | - | $28.0K | $3.0K | $0 | - | ($17.0K) | $0 | $24.0K | - |
| Net Income | ($4.14M) | - | ($4.30M) | $2.39M | $38.01M | - | ($21.91M) | ($19.05M) | ($31.75M) | - |
| EPS - Basic | ($0.29) | - | ($0.32) | $0.20 | $3.53 | - | ($2.93) | ($3.10) | ($5.75) | - |
| EPS - Diluted | ($0.29) | - | ($0.32) | $0.19 | $3.50 | - | ($2.93) | ($3.10) | ($5.75) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.36M | $8.48M | $5.74M | $16.90M | $13.84M | $25.03M | $46.45M | $31.31M | $35.09M | $25.84M |
| Accounts Receivable | $0 | $1.25M | $1.91M | $0 | $8.88M | $1.48M | $1.33M | $2.42M | $35.83M | $34.11M |
| Inventory | - | $0 | $0 | $0 | $0 | $10.65M | $13.98M | $18.75M | $16.08M | $9.71M |
| Accounts Payable | $637.0K | $127.0K | $318.0K | $1.76M | $1.38M | $4.37M | $2.15M | $5.25M | $2.85M | $3.68M |
| Current Assets | $12.17M | $12.21M | $18.43M | $24.77M | $27.18M | $64.89M | $91.86M | $62.41M | $106.43M | $101.87M |
| Total Assets | $20.00M | $20.23M | $30.17M | $36.90M | $62.04M | $109.10M | $142.71M | $117.28M | $165.27M | $165.50M |
| Current Liabilities | $5.64M | $14.92M | $18.06M | $14.56M | $47.89M | $134.57M | $155.98M | $148.27M | $180.69M | $142.23M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $57.31M | $58.74M | $66.80M | $71.94M | $117.11M | $206.38M | $233.25M | $228.15M | $263.58M | $264.74M |
| Stockholders' Equity | ($37.31M) | ($38.50M) | ($36.63M) | ($35.04M) | ($55.07M) | ($97.28M) | ($90.54M) | ($110.87M) | ($98.31M) | ($99.23M) |
| Retained Earnings | ($2.03B) | ($2.02B) | ($2.02B) | ($2.01B) | ($2.02B) | ($2.05B) | ($2.04B) | ($2.02B) | ($2.00B) | ($1.97B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.07M) | - | - | - | ($28.14M) | - | - | - | ($29.61M) | - |
| Investing Cash Flow | $0 | - | - | - | $17.20M | - | - | - | $14.72M | - |
| Financing Cash Flow | $2.95M | - | - | - | ($250.0K) | - | - | - | $24.14M | - |
| CapEx | - | - | - | - | $0 | - | - | - | $127.0K | - |
| Free Cash Flow | - | - | - | - | ($28.14M) | - | - | - | ($29.74M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -652.9% | - | -103.5% | 18.2% | 141.8% | - | - | - | - | - |
| EBITDA margin | -647.3% | - | - | - | 148.4% | - | - | - | - | - |
| Net margin | -803.3% | - | -124.6% | 13.6% | 138.9% | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | -102.9% | - | - | - | - | - |
| FCF / Net income | - | - | - | - | -0.74 | - | - | - | 0.94 | - |
| R&D / Revenue | 31.8% | - | 84.7% | 41.6% | 100.3% | - | - | - | - | - |
| SG&A / Revenue | 697.1% | - | 115.5% | 37.1% | 41.9% | - | - | - | - | - |
| Effective tax rate | - | - | - | 0.1% | 0.0% | - | - | - | - | - |
| Return on assets | -20.7% | - | -14.3% | 6.5% | 61.3% | - | -15.4% | -16.2% | -19.2% | - |
| Return on equity | 11.1% | - | 11.7% | -6.8% | -69.0% | - | 24.2% | 17.2% | 32.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.16 | 0.82 | 1.02 | 1.70 | 0.57 | 0.48 | 0.59 | 0.42 | 0.59 | 0.72 |
| Quick ratio | 2.16 | 0.82 | 1.02 | 1.70 | 0.57 | 0.40 | 0.50 | 0.29 | 0.50 | 0.65 |
| Cash ratio | 1.48 | 0.57 | 0.32 | 1.16 | 0.29 | 0.19 | 0.30 | 0.21 | 0.19 | 0.18 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -4.1x | - | -3.9x | 3.3x | 38.2x | - | -18.4x | -14.4x | -27.1x | - |
| Equity multiplier | -0.54 | -0.53 | -0.82 | -1.05 | -1.13 | -1.12 | -1.58 | -1.06 | -1.68 | -1.67 |
| Liabilities / Assets | 2.87 | 2.90 | 2.21 | 1.95 | 1.89 | 1.89 | 1.63 | 1.95 | 1.59 | 1.60 |
| Efficiency | ||||||||||
| Asset turnover | 0.03 | - | 0.11 | 0.48 | 0.44 | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 0d | - | 202d | 0d | 118d | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | 40.6x | 1.7x | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | 129.1x | - | 56.3x | 5.4x | 2.4x | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | 1.2x | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -98.1% | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | 83.6% | - | - | - | 68.7% | 74.5% | 58.3% | - |
| Net income growth (YoY) | - | - | 80.4% | - | - | - | 68.6% | 73.2% | 57.5% | - |
| EPS growth (YoY) | - | - | 89.1% | - | - | - | -343.9% | -355.9% | -560.9% | - |
| EPS CAGR (3y) | - | - | - | 1.8% | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | 5.4% | - | - | - | 23.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 32.2% | 60.4% | 59.5% | 68.4% | 44.0% | 2.0% | -78.1% | - | - | - |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Atara Biotherapeutics against the 5 most active filers in the same SIC group.